Matthew Vincent Dolan Sells 1,990 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the transaction, the executive vice president now directly owns 42,377 shares in the company, valued at approximately $5,839,974.37. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

DexCom Trading Up 0.3 %

Shares of NASDAQ DXCM opened at $134.30 on Friday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. The stock has a market capitalization of $51.77 billion, a P/E ratio of 102.52, a price-to-earnings-growth ratio of 2.35 and a beta of 1.20. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The business has a fifty day moving average price of $129.35 and a 200 day moving average price of $116.41.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. The firm had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The firm’s quarterly revenue was up 26.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.34 EPS. Equities research analysts expect that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on DXCM. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. UBS Group upped their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Citigroup upped their price objective on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Royal Bank of Canada began coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. Finally, Raymond James increased their price target on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 23rd. Two equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $141.40.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Cary Street Partners Investment Advisory LLC raised its position in DexCom by 11.1% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock valued at $108,000 after acquiring an additional 115 shares in the last quarter. CX Institutional purchased a new position in DexCom during the fourth quarter valued at approximately $286,000. Cerity Partners LLC raised its position in DexCom by 5,791.0% during the fourth quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company’s stock valued at $57,574,000 after acquiring an additional 456,097 shares in the last quarter. Turtle Creek Wealth Advisors LLC purchased a new position in DexCom during the fourth quarter valued at approximately $57,000. Finally, Intelligence Driven Advisers LLC purchased a new position in DexCom during the third quarter valued at approximately $525,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.